Informace o publikaci

Final 5-year findings from the phase 3 HELIOS study of ibrutinib plus bendamustine and rituximab in patients with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma

Autoři	FRASER GAM CHANAN-KHAN A DEMIRKAN F RS Silva GROSICKI S JANSSENS A MAYER Jiří BARTLETT NL DILHUYDY MS LOSCERTALES J AVIGDOR A RULE S SAMOILOVA O PAVLOVSKY MA GOY A MATO A HALLEK M SALMAN M TAMEGNON M SUN S CONNOR A NOTTAGE K SCHUIER N BALASUBRAMANIAN S HOWES A CRAMER P
Rok publikování	2020
Druh	Článek v odborném periodiku
Časopis / Zdroj	LEUKEMIA & LYMPHOMA
Citace
Doi	http://dx.doi.org/10.1080/10428194.2020.1795159
Klíčová slova	Ibrutinib; HELIOS phase 3 trial; 5-year follow-up; overall survival; relapsed chronic lymphocytic leukemia
Popis	We report final analysis outcomes from the phase 3 HELIOS study (NCT01611090). Patients with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma without deletion 17p (n = 578) were randomized 1:1 to 420 mg daily ibrutinib or placebo plus <= 6 cycles of bendamustine plus rituximab (BR), followed by ibrutinib or placebo alone. Median follow-up was 63.7 months. Median investigator-assessed progression-free survival was longer with ibrutinib plus BR (65.1 months) than placebo plus BR (14.3 months; hazard ratio [HR] 0.229 [95% confidence interval (CI) 0.183-0.286];p < .0001). Despite crossover of 63.3% of patients from the placebo plus BR arm to ibrutinib treatment upon disease progression, ibrutinib plus BR versus placebo plus BR demonstrated an overall survival benefit (HR 0.611 [95% CI 0.455-0.822];p = .0010; median not reached in either arm). Long-term follow-up data confirm the survival benefit of ibrutinib plus BR over BR alone. Safety profiles were consistent with those known for ibrutinib and BR.